

---

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

**MYRIAD GENETICS INC**

---

(Name of Issuer)

**Common Stock, par value \$0.01 per share**

---

(Title of Class of Securities)

**62855J104**

---

(CUSIP Number)

**01/06/2026**

---

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)
- 
- 

SCHEDULE 13G

CUSIP No. 62855J104

Names of Reporting Persons

1

GLENVIEW CAPITAL MANAGEMENT, LLC

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Number of Shares 5 Sole Voting Power

Beneficially	0.00
Owned by	Shared Voting Power
Each	6
Reporting	4,941,058.00
Person	Sole Dispositive Power
With:	7
	0.00
	Shared Dispositive
	8 Power
	4,941,058.00
	Aggregate Amount Beneficially Owned by Each Reporting Person
9	4,941,058.00
	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
10	<input type="checkbox"/>
	Percent of class represented by amount in row (9)
11	5.3 %
	Type of Reporting Person (See Instructions)
12	OO

## SCHEDULE 13G

**CUSIP No.** 62855J104

	Names of Reporting Persons
1	ROBBINS LARRY
	Check the appropriate box if a member of a Group (see instructions)
2	<input type="checkbox"/> (a)
	<input type="checkbox"/> (b)
3	Sec Use Only
	Citizenship or Place of Organization
4	UNITED STATES
	Sole Voting Power
	5
	0.00
Number of	Shared Voting Power
Shares	6
Beneficially	4,941,058.00
Owned by	Sole Dispositive Power
Each	7
Reporting	0.00
Person	Shared Dispositive
With:	8 Power
	4,941,058.00
	Aggregate Amount Beneficially Owned by Each Reporting Person
9	4,941,058.00
	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
10	<input type="checkbox"/>
11	Percent of class represented by amount in row (9)

5.3 %

Type of Reporting Person (See Instructions)

12

IN, HC

## SCHEDULE 13G

### Item 1.

Name of issuer:

(a)

MYRIAD GENETICS INC

Address of issuer's principal executive offices:

(b)

322 North 2200 West, Salt Lake City, Utah, 84116

### Item 2.

Name of person filing:

This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"): i. Glenview Capital Management, LLC ("Glenview Capital Management") ii. Larry Robbins ("Mr. Robbins"). This Statement relates to shares of Common Stock, par value \$0.01 per share ("Shares") held for the accounts of Glenview Capital Master Fund, Ltd., a Cayman Islands exempted company ("Glenview Capital Master Fund"), Glenview Offshore Opportunity Master Fund, Ltd., a Cayman Islands exempted company ("Glenview Offshore Opportunity Master Fund"), and Glenview Healthcare Master Fund, L.P., a Cayman Islands limited partnership ("Glenview Healthcare Master Fund"). Glenview Capital Management serves as investment manager to each of Glenview Capital Master Fund, Glenview Offshore Opportunity Master Fund and Glenview Healthcare Master Fund. Mr. Robbins is the Chief Executive Officer of Glenview Capital Management.

(a)

Address or principal business office or, if none, residence:

(b)

The address of the principal business office of each of the Reporting Persons is 520 Madison Avenue, 33rd Floor, New York, New York 10022.

Citizenship:

(c)

i. Glenview Capital Management is a Delaware limited liability company ii. Mr. Robbins is a citizen of the United States of America.

Title of class of securities:

(d)

Common Stock, par value \$0.01 per share

CUSIP No.:

(e)

62855J104

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

### Item 4. Ownership

(a)

Amount beneficially owned:

As of January 12, 2026, each of the Reporting Persons may be deemed the beneficial owner of 4,941,058 Shares. This amount consists of: (A) 1,886,965 Shares held for the account of Glenview Capital Master Fund; (B) 2,791,657 Shares held for the account of Glenview Offshore Opportunity Master Fund; and (C) 262,436 Shares held for the account of Glenview Healthcare Master Fund.

Percent of class:

(b) As of January 12, 2026, each of the Reporting Persons may be deemed the beneficial owner of approximately 5.30% of the Shares outstanding. (There were 93,213,722 Shares outstanding as of October 31, 2025, based on the Issuer's quarterly report on Form 10-Q filed on November 4, 2025.) %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

0

(ii) Shared power to vote or to direct the vote:

4,941,058.00

(iii) Sole power to dispose or to direct the disposition of:

0

(iv) Shared power to dispose or to direct the disposition of:

4,941,058.00

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

See disclosure in Items 2 and 4 hereof. Certain funds listed in Item 2(a) are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares covered by this Statement that may be deemed to be beneficially owned by the Reporting Persons.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

See disclosure in Item 2 hereof.

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

GLENVIEW CAPITAL MANAGEMENT, LLC

Signature: /s/ Mark J. Horowitz

Name/Title: Mark J. Horowitz, Co-President

Date: 01/13/2026

ROBBINS LARRY

Signature: /s/ Mark J. Horowitz

Name/Title: Mark J. Horowitz, attorney-in-fact for Larry  
Robbins

Date: 01/13/2026

**Exhibit Information**

Exhibit 1: Joint Filing Agreement Exhibit 2: Power of Attorney

**JOINT FILING AGREEMENT**

The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Myriad Genetics, Inc. dated as of January 13, 2026 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

**GLENVIEW CAPITAL MANAGEMENT, LLC**

By: /s/ Mark J. Horowitz  
Mark J. Horowitz  
Co-President of Glenview Capital Management, LLC

**LARRY ROBBINS**

By: /s/ Mark J. Horowitz  
Mark J. Horowitz, attorney-in-fact for Larry Robbins

January 13, 2026

**POWER OF ATTORNEY**

KNOW ALL MEN BY THESE PRESENT, that I, Larry Robbins, hereby make, constitute and appoint Mark J. Horowitz, acting individually, as my agent and attorney-in-fact for the purpose of executing in my name, (a) in my personal capacity or (b) in my capacity as Chief Executive Officer or in other capacities of Glenview Capital Management, LLC, a Delaware limited liability company, and each of its affiliates or entities advised or controlled by me or Glenview Capital Management, LLC, all documents, certificates, instruments, statements, filings and agreements (“documents”) to be filed with or delivered to any foreign or domestic governmental or regulatory body or required or requested by any other person or entity pursuant to any legal or regulatory requirement relating to the acquisition, ownership, management or disposition of securities, futures contracts or other investments, and any other documents relating or ancillary thereto, including, without limitation, all documents relating to filings with the United States Securities and Exchange Commission (the “SEC”) pursuant to the Securities Act of 1933, as amended, or the Securities and Exchange Act of 1934, as amended (the “Act”), and the rules and regulations promulgated thereunder, including, without limitation: (1) all documents relating to the beneficial ownership of securities required to be filed with the SEC pursuant to Section 13(d) or Section 16(a) of the Act, including, without limitation: (a) any acquisition statements on Schedule 13D or Schedule 13G and any amendments thereto, (b) any joint filing agreements pursuant to Rule 13d-1(k), and (c) any initial statements of, or statements of changes in, beneficial ownership of securities on Form 3, Form 4 or Form 5 and (2) any information statements on Form 13F required to be filed with the SEC pursuant to Section 13(f) of the Act.

All past acts of the attorney-in-fact in furtherance of the foregoing are hereby ratified and confirmed.

This Power of Attorney revokes the previous Power of Attorney, executed by the undersigned on February 10, 2009, and shall remain in effect until revoked, in writing, by the undersigned.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney, this 2nd day of February, 2016.

/s/ Larry Robbins

Larry Robbins